Oligoastrocytoma secondary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Patients treated for oligoastrocytoma should follow-up for secondary prevention. Secondary prevention strategies following oligoastrocytoma include a clinical assessment of neurological function and [[corticosteroid]] usage (Macdonald criteria), checking for signs of [[venous thromboembolism]], regular laboratory tests, and routine imaging (MRI and Positron Emission Tomography) at scheduled intervals after treatment.<ref name="pmid20555079">{{cite journal| author=Stupp R, Tonn JC, Brada M, Pentheroudakis G, ESMO Guidelines Working Group| title=High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | journal=Ann Oncol | year= 2010 | volume= 21 Suppl 5 | issue= | pages= v190-3 | pmid=20555079 | doi=10.1093/annonc/mdq187 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20555079 }} </ref> | |||
Patients treated for oligoastrocytoma should follow-up for secondary prevention. Secondary prevention strategies following oligoastrocytoma include a clinical assessment of neurological function and [[corticosteroid]] | |||
==Secondary Prevention== | ==Secondary Prevention== | ||
===Follow up after treatment=== | ===Follow up after treatment=== | ||
Patients treated for oligoastrocytoma should follow-up for secondary prevention. Follow-up measures are shown in the table below:<ref name=" | Patients treated for oligoastrocytoma should follow-up for secondary prevention. Follow-up measures are shown in the table below:<ref name="pmid20555079">{{cite journal| author=Stupp R, Tonn JC, Brada M, Pentheroudakis G, ESMO Guidelines Working Group| title=High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | journal=Ann Oncol | year= 2010 | volume= 21 Suppl 5 | issue= | pages= v190-3 | pmid=20555079 | doi=10.1093/annonc/mdq187 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20555079 }} </ref> | ||
*Clinical assessment of [[neurology|neurological function]] | *Clinical assessment of [[neurology|neurological function]] | ||
*Tapering [[steroid]] usage as early as possible | *Tapering [[steroid]] usage as early as possible | ||
*Checking for signs of [[venous thromboembolism]] | *Checking for signs of [[venous thromboembolism]] | ||
Revision as of 14:47, 19 October 2015
|
Oligoastrocytoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Oligoastrocytoma secondary prevention On the Web |
|
American Roentgen Ray Society Images of Oligoastrocytoma secondary prevention |
|
Risk calculators and risk factors for Oligoastrocytoma secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]
Overview
Patients treated for oligoastrocytoma should follow-up for secondary prevention. Secondary prevention strategies following oligoastrocytoma include a clinical assessment of neurological function and corticosteroid usage (Macdonald criteria), checking for signs of venous thromboembolism, regular laboratory tests, and routine imaging (MRI and Positron Emission Tomography) at scheduled intervals after treatment.[1]
Secondary Prevention
Follow up after treatment
Patients treated for oligoastrocytoma should follow-up for secondary prevention. Follow-up measures are shown in the table below:[1]
- Clinical assessment of neurological function
- Tapering steroid usage as early as possible
- Checking for signs of venous thromboembolism
- Laboratory tests
- Generally not indicated, unless patient is on chemotherapy (complete blood count), steroids (glucose level), and anticonvulsants (complete blood count and liver function tests)
- MRI every 3-4 months
- Positron emission tomography
| Follow up | Description |
|---|---|
|
|
|
|
|
Scans are performed at routine intervals as follows:
|
|
|
|
|
Table adapted from Pfister DG, et al. Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2013;11(8):917-23.[2]
References
- ↑ 1.0 1.1 Stupp R, Tonn JC, Brada M, Pentheroudakis G, ESMO Guidelines Working Group (2010). "High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". Ann Oncol. 21 Suppl 5: v190–3. doi:10.1093/annonc/mdq187. PMID 20555079.
- ↑ Pfister DG, Ang KK, Brizel DM, Burtness BA, Busse PM, Caudell JJ; et al. (2013). "Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines". J Natl Compr Canc Netw. 11 (8): 917–23. PMID 23946171.